NCT02468661: A trial that was reported late by Novartis Pharmaceuticals
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT02468661 |
|---|---|
| Title | A Phase Ib/II, Open-label, Multicenter Trial With Oral cMET Inhibitor INC280 Alone and in Combination With Erlotinib Versus Platinum With Pemetrexed in Adult Patients With EGFR Mutated, cMET-amplified, Locally Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC) With Acquired Resistance to Prior EGFR Tyrosine Kinase Inhibitor (EGFR TKI) |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Sept. 23, 2015 |
| Completion date | March 31, 2020 |
| Required reporting date | March 31, 2021, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 3, 2020 |
| Days late | None |